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Abstract
Background: The common failure of health systems to ensure adequate and sufficient supplies of
injection devices may have a negative impact on injection safety. We conducted an assessment in
April 2001 to determine to which extent an increase in safe injection practices between 1995 and
2000 was related to the increased access to injection devices because of a new essential medicine
policy in Burkina Faso.
Methods: We reviewed outcomes of the new medicine policy implemented in1995. In April 2001,
a retrospective programme review assessed the situation between 1995 and 2000. We visited 52
health care facilities where injections had been observed during a 2000 injection safety assessment
and their adjacent operational public pharmaceutical depots. Data collection included structured
observations of available injection devices and an estimation of the proportion of prescriptions
including at least one injection. We interviewed wholesaler managers at national and regional levels
on supply of injection devices to public health facilities.
Results: Fifty of 52 (96%) health care facilities were equipped with a pharmaceutical depot selling
syringes and needles, 37 (74%) of which had been established between 1995 and 2000. Of 50
pharmaceutical depots, 96% had single-use 5 ml syringes available. At all facilities, patients were
buying syringes and needles out of the depot for their injections prescribed at the dispensary. While
injection devices were available in greater quantities, the proportion of prescriptions including at
least one injection remained stable between 1995 (26.5 %) and 2000 (23.8 %).
Conclusion: The implementation of pharmaceutical depots next to public health care facilities
increased geographical access to essential medicines and basic supplies, among which syringes and
needles, contributing substantially to safer injection practices in the absence of increased use of
therapeutic injections.
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Background
Injections are one of the most common medical proce-
dures, with an estimated 16 thousand million injections
administered each year in developing and transitional
countries, most of which are for therapeutic purposes [1].
In these developing and transitional countries, WHO esti-
mates that 39% of injections are administered with
syringes and/or needles re-used in the absence of steriliza-
tion [1]. WHO's Global Burden of Disease study suggests
that annually, in developing and transitional countries,
32% of new hepatitis B virus (HBV) infections, 40% of
new hepatitis C virus (HCV) infections and 5% of new
human immunodeficiency virus (HIV) infections are
attributable to contaminated health-care injections [2]. To
prevent injection-associated infections, WHO recom-
mends a policy based upon (1) behaviour change among
patients and health care workers to reduce injection over-
use and improve safety, (2) provision of injection devices
and infection control supplies and (3) sharps waste man-
agement.
The common failure of health systems to ensure adequate
and sufficient supplies of injection devices may have a
negative impact on injection safety. The WHO model list
of essential medicines made no mention of the need to
supply injection devices in quantities that matched sup-
plies of essential injectable medicines although 44% of
active ingredients were mentioned in injectable form [3].
In a system analysis conducted in 1995, the logistics
project of WHO's African Regional Office (AFRO) identi-
fied the failure to systematically fund sufficient supplies of
injection devices as part of immunization services as a key
determinant of widespread reuse of syringes and needles
in absence of sterilization [4]. In 2000, WHO, the United
Nations Children's fund (UNICEF), the United Nations
Population Fund (UNFPA) recommended in a Joint State-
ment that sufficient syringes and safety boxes be supplied
with consignments of vaccines to address the issue of
insufficient supplies of injection devices for immuniza-
tion purposes [5]. In the curative health care sector where
95% of all injections are provided, the concept of injec-
tion device security entails that injectable medicines, dilu-
ents, single-use injection devices and safety boxes are
supplied in timely manner and adequate quantities [6].
However, it has not yet been implemented on the large
scale.
Burkina Faso is a good setting to examine how access to
injection devices impacts on injection safety. In 1995, an
injection safety assessment indicated that (1) sterile injec-
tion devices were used for each injection in 80% of the
urban health care facilities, 60% of provincial facilities
and 11% of the rural facilities and (2) up to 48% of health
care facilities visited reported insufficient quantities of
injection devices available [4]. In contrast, the results of a
second assessment carried out in 2000 on a sample repre-
sentative of the facilities in the country suggested that
practices had substantially improved [7]. In 96% of the 52
health care facilities visited, a new syringe and a new nee-
dle were used for each patient and that there were no
shortages of injection devices. At 49 of the 52 health care
facilities (94%), injection devices needed to administer
injectable medicines were systematically prescribed for
treatment. A discussion of the results generated the
hypothesis that the new national essential medicine pol-
icy that promoted a better access to medicines and single-
use injection devices had made an important and substan-
tial contribution to safer injection practices [8-10]. In
April 2001, we conducted a programme review to better
document how the new national essential medicines pol-
icy had contributed to safer injection practices (Figure 1).
The objectives of this programme review were (1) to iden-
tify the features of the national essential medicines policy
that might have influenced injection practices, (2) to
quantify the improved access to injection devices between
1995 and 2000, (3) to determine whether an increased
access to injection devices could have led to irrational use
of injections and (4) to identify potential adverse effects
of the increased availability of injection devices on sharps
waste management.
Methods
Survey design and sampling
We conducted a cross-sectional survey in 2001 to assess
retrospectively the situation between 1995 (the year of the
initial injection safety survey that was also the year of
implementation of the new national policy to improve
access to essential medicines) and 2000 (the year of the
Sequence of the injection safety assessments in Burkina Faso  that led to the programme review reported in this article,  1995–2001 Figure 1
Sequence of the injection safety assessments in Burkina Faso 
that led to the programme review reported in this article, 
1995–2001.
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Could the new essential medicine
policy have increased access to injection devices
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survey suggesting better injection practices, Figure 1)
[11,12]. For this 2001 programme review, we sampled
and re-visited the 52 health care facilities where injections
had been observed among the 80 included in the 2000
injection safety assessment. The 2000 injection safety
assessment used a two-stage cluster sample made of eight
clusters of 10 health care facilities. At each of the 52 facil-
ities visited in April 2001, we selected randomly 30 pre-
scriptions for each month of June between 1995 and 2000
and visited the adjacent public pharmaceutical depots.
Finally, we interviewed the managers of the 11 district
wholesalers supplying the 52 facilities included in the
sample.
Data collection
Standardized data collection included (1) structured
observations of injection devices available in the health
facility, (2) reviews of the registers to estimate the propor-
tion of prescriptions including at least one injection dur-
ing the months of June between 1995 and 2000, (3)
interviews of health care workers using standardized ques-
tionnaires, (4) interviews of operational public pharma-
ceutical depots managers using standardized
questionnaires, (5) structured observations of 5 ml
syringes with needle and 15 basic essential medicines
available in the depot (chosen as sentinel indicators of
availability and good stock management) and (6) struc-
tured interviews of district wholesalers managers. We
recorded the origin and brand name of injection devices
observed and the sale prices of syringes and needles in the
pharmaceutical depots. Seven teams of two investigators
collected the information. All teams standardized their
data collection procedure before the fieldwork through
training and a field visit.
Other information regarding injection devices
We interviewed the manager of the national wholesaler
who provided figures estimating the number of injection
devices sold annually in the public health care sector and
fixed retail prices. We converted the retail prices of
syringes and needles in the public sector set by the Minis-
try of Health in US$ according to the exchange rate in use
in May 2001 (1 US$ for 750 Francs CFA). We used the
standard set of medicines and basic consumables given to
open a pharmaceutical depot in Burkina Faso by Non-
governmental Organizations (NGOs) with the Ministry of
Health approval to estimate the proportion of the essen-
tial medicines expenditure used to procure injection
devices. This standard package was representative of a typ-
ical consumption of a depot and covered the need of a
population of 10 000 persons for three to six months in
Burkina Faso. Finally, we reviewed the major changes in
the new national essential medicines policy, particularly
related to access to medicines and basic supplies, includ-
ing the number of operational pharmaceutical depots set
up throughout the country annually and the regulation of
medicine retailed prices in the public sector.
Data analysis
We entered and analysed data using the version 1.2d of
the Sphinx plus software (Le Sphinx Développement,
Chavanod, France). Proportions were calculated using the
number of health care facilities visited (52), the number
of pharmaceutical depots or the number of health care
workers interviewed as denominator, as appropriate.
Protection of human subjects
The Ministry of Health approved the protocol and pro-
vided an introduction letter for the visit of health care
facilities. We met each regional director prior to field visits
in each area. However, there was no communication with
the health care facilities prior to the arrival of the field
workers. We informed participants about the purpose of
the assessment and about their right to refuse. Participa-
tion was voluntary for all interviewed. When injections
were about to occur with non-sterile devices, field workers
were asked to interrupt tactfully the procedure. All infor-
mation was collected confidentially using codes.
Results
Improved geographical access to community pharmacies 
and injection devices
Geographical access to injection devices improved sub-
stantially between 1995 and 2000. Of the 52 health care
facilities visited in April 2001, 50 (96%) were equipped
with a public sector pharmaceutical depot selling syringes
and needles directly to patients. Of these, 37 (74%) had
been established between 1995 and 2000 (Figure 2). For
the two remaining facilities, one had a private depot sup-
plied by private distribution mechanisms and the other
had a non-operational depot. Of 50 public pharmaceuti-
cal depots visited, 48 (96%) had single-use 5 ml syringes
available. An average of 12 out of the 15 key essential
medicines selected from the national drug formulary
(79%) were actually in stock in the 50 depots at the time
of the assessment. At all health care facilities, patients
were buying syringes and needles at the depot for the
injections that had been prescribed at the dispensary.
Overall, the number of single-use 5 ml syringes sold and
distributed by the national wholesaler to the network of
public pharmaceutical depots increased from 880,000 in
1996 to 1,840,000 in 2000.
Price of injection devices and user fees
The Ministry of Health fixed the prices of injection devices
nationally. The retail price of 2 ml, 5 ml and 10 ml syringe
and needle sets did not vary between 1997, 1998 and
2000 (About 10 US$ cents for 5 ml syringes, Figure 3). Of
the 52 health care facilities visited, six centres (12%)
charged a flat fee for the procedure of injection adminis-BMC Public Health 2005, 5:136 http://www.biomedcentral.com/1471-2458/5/136
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tration that ranged from three to 26 US$ cents. In 2000,
the cost of single-use syringes and needles represented 32
US$ (2.2%) of the 1,430 US$ total cost of a start-up set of
medicines and medical supplies given to primary health
care facilities to open a pharmaceutical depot.
Rational use of medicines and sharps waste management
While injection devices were available in greater quanti-
ties, the proportion of prescriptions including at least one
injection remained stable around 25% between 1995 and
2000 (Figure 4). In contrast, the proportion of prescrip-
tions including at least one antibiotic increased between
1995 and 2000 and the average number of medicines per
prescription increased from 1.8 in 1995 to 2.7 in 2000. Of
the 52 health care workers interviewed (one per health
facility), 37 (71%) participated in an in-service training
course on rational use of medicines and 12 (23%)
attended a training course that also addressed good injec-
tion practice. With respect to sharps waste management,
we observed used sharps in the vicinity of 46 (88%) of the
52 health care facilities visited.
Discussion
Despite differences in methodologies, the results of the
consecutive injection safety assessments suggested an
improvement of injection practices between 1995 and
2000 in Burkina Faso. The implementation of pharma-
ceutical depots next to health care facilities increased geo-
graphical access to essential medicines and syringes and
needles and contributed to an increased use of single-use
injection devices. Since the retail prices of injection
devices remained unchanged, the improvement in the use
is likely to be a consequence of an improved geographical
access rather than a consequence of improved financial
access. Use of therapeutic injections did not increased
substantially during the same period as a result of the
increased availability of injection devices. However, use of
other medicines, including antibiotics, did increase as the
availability of medicines increased in the depots. The dif-
ferent trends observed for antibiotics and injections
would suggest that increased availability of injection
devices did not lead to overuse of injections.
The number of pharmaceutical depots established in
health care facilities dramatically increased between 1995
and 2000. In 1995, the Ministry of Health of Burkina Faso
reformed the national essential medicines policy to estab-
lish pharmaceutical depots for the delivery of essential
medicines and essential medical consumables including
injection devices. In 1998, the Ministry of Health further
supported this move and decided to systematically set up
pharmaceutical depots for all new health care facilities.
The strong commitment of the government to improve
geographical and financial access to essential medicines
and consumables increased access to injection devices.
These pharmaceutical depots were managed according to
the Bamako Initiative's cost recovery scheme. In Burkina
Faso, the distribution system supplies injection devices
and injectable medicines through the same channel. This
allows supplying matching quantities of injection devices
and injectable medicines in the same way that immuniza-
tion services supply vaccines, auto-disable syringes and
safety boxes together as per the "bundling" principles [5].
To maintain prices affordable for the majority of the com-
munity, the Ministry of Health fixed retail prices of essen-
tial medicines and consumables included in the national
list of essential medicines and reviewed those on an
annual basis. As a result, the retail price of single-use
syringes and needles sets remained stable from 1997 to
2001. In addition, to improve affordability for the popu-
lation, the government decided the exoneration of impor-
tation taxes for essential medicines and essential
consumables included in the national list of essential
medicines. As retail prices remained stable since 1997, the
improvement of the geographical access to injection
devices is probably the key factor that contributed to the
increased use of single-use injection devices to administer
injections in primary health care.
The investment made to procure single-use syringes and
needles together with essential medicines was not of a
high magnitude. Our analysis suggests that it represented
a small proportion (2.2%) of the essential medicines
expenditure [3]. In the curative sector, the incremental
cost of a set of syringes and needles to ensure injection
Proportion of 52 health care facilities visited in 2001 that  were equipped with a functional pharmaceutical depot, 1990  – 2000, Burkina Faso Figure 2
Proportion of 52 health care facilities visited in 2001 that 
were equipped with a functional pharmaceutical depot, 1990 
– 2000, Burkina Faso. (Assessed through asking the date of 
opening of the pharmaceutical depot in each of the health 
care facilities visited).
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safety (5 cents US$ per set as international retail price) is
moderate (around 10%) when compared with the average
cost of an injectable medicine (the median international
retail price for 104 injectable medicines included in the
WHO model list of essential medicines was 0.5 US$) [3].
Thus, joint procurement of injectable medicines and sin-
gle-use injection devices should not lead to a substantial
increase of essential medicines expenditures in develop-
ing and transitional countries [3]. The national list of
essential medicines must play a role in ensuring that the
injectable medicines included are limited to the mini-
mum so that unnecessary injections can be avoided. In
this way, funds can be saved to finance syringes and nee-
dles for those injections that are necessary. Interventions
to procure single-use injection devices to ensure injection
safety are highly cost-effective health interventions [13].
While single-use injection devices should be made availa-
ble in every health care facilities, they should also be made
available in a way that ensures equity. In Burkina Faso, the
poorest part of the population may not be able to assume
the financial burden of single-use injection devices
according to the Bamako Initiative. The use of cost recov-
ery scheme could decrease service utilization by the gen-
eral population and subsequently expose the poorest to
unsafe injection practices and reuse of single-use injection
devices [14]. The low frequency of reuse of injection
devices in the 2000 injection safety survey suggests that
the price of syringes and needles was not an obstacle to
safe injections. However, the cost recovery issue is broader
than the specific problem of access to injection devices.
Equitable financing mechanisms avoiding user's fees for
poor people should facilitate access to safe health care,
essential medicines and injection devices for the poorest
part of the population.
The generalized use of single-use injection devices in pre-
ventive and curative services has not led to major side
effects in Burkina Faso. Excessive availability of injectable
medicines can increase irrational use of injections and
restricted access to injectable medications is associated
with a reduction of injection overuse [15]. However, in
Burkina Faso, the indicators selected to measure the use of
injectable medicines did not suggest that the increased use
of single-use injection devices led to an increase of the
irrational use of injections. The implementation of the
national essential medicines policy promoted the appro-
priate use of injectable medicines through limiting the
number of injectable medicines on the national list of
essential medicines and through training prescribers on
the appropriate use of medicines. While an increased
access to syringes and needles did not affect injection fre-
quency, final disposal of used syringes remained a prob-
lem [7]. Making injections safe to the recipients should be
the first priority from a public health point of view as the
burden of disease associated with unsafe sharps waste dis-
posal is of lower magnitude than the one associated with
reuse of injection devices in absence of sterilization
[2,16]. Nevertheless, a national sharps waste management
policy that is planned, costed and budgeted is needed
along with training of the health care workers to ensure
appropriate sharps waste management.
Increased access to injection devices is not the only expla-
nation that may account for the improvement of injection
practices in Burkina Faso. Increased awareness regarding
risks of transmission of pathogens, including HIV,
through unsafe injections among the population may
have played a role [7,17,18]. In 1994, a study reported
that 16.9% of the pregnant women, 25.4% of the long-
distance truck drivers and 11.5% of the sex-workers inter-
viewed knew about the risk of HIV transmission through
contaminated syringes and needles [17]. In 2000, a sec-
ond study indicated that 60.4% of the persons randomly
selected in Bobo-Dioulasso, the second largest city in
Burkina, knew about the possibility of HIV transmission
through injections [18]. While these two studies were car-
ried out in different populations, an increase in the aware-
ness regarding the risk of HIV transmission through
injections cannot be excluded [7]. This awareness of risks
may have increased consumers' demand for safe single-
use syringes. In areas of the world where the awareness
regarding unsafe injections is low (e.g., South Asia), [1]
good geographical access to injection devices may not be
associated with safe practices.
This programme review suffers from three main limita-
tions. First, the 1995 and 2000 assessments used different
Official retail price of 2 ml, 5 ml and 10 ml syringes and nee- dles set, 1997 – 2000, at pharmaceutical depots, Burkina Faso Figure 3
Official retail price of 2 ml, 5 ml and 10 ml syringes and nee-
dles set, 1997 – 2000, at pharmaceutical depots, Burkina Faso 
(obtained from the national wholesaler).
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methodologies and the 1995 assessment did not use
standard WHO methods [7] However, three elements sug-
gest that the apparent improvement between 1995–1996
and 2000 is real. The proportion of use of sterile devices
observed in urban facilities in 1995 (80%) is still below
the lower 95% confidence limit of the proportion of use
of sterile devices reported nationwide in the 2000 assess-
ment (85%). The majority of primary health care facilities
in Burkina Faso are located in rural area where the propor-
tion of use of sterile devices was 11% in 1995, contrasting
with the 96% national average in 2000. The methodology
used in 1995 was a convenience sample likely to have
excluded remote primary health care facilities, which
could have lead to an optimistic assessment of injection
practices. Second, we used the availability of selected
types of injection devices during the field visit as an indi-
cator of access. This method may not have captured short-
ages that would have occurred before or after the visit.
However, this indicator was chosen as (1) it is compatible
with other access indicators used to monitor essential
medicine policies [19] and (2) it was simple, reproducible
and objective. Third, this assessment focused only on the
public sector. Thus, we cannot rule out that the cost recov-
ery scheme in place in public health care facilities would
have driven patients to the private sector. However, this is
unlikely to have happened because Burkina Faso does not
have an major informal private sector [14] and because
the formal private sector has user's fees that are generally
higher than those in place in the public sector.
One element of the strategy to ensure injection safety is a
continuous availability of sufficient quantities of injection
Rational drug use indicators during the months of June in 52 primary health care facilities of Burkina Faso visited in 2001, 1995– 2000 Figure 4
Rational drug use indicators during the months of June in 52 primary health care facilities of Burkina Faso visited in 2001, 1995–
2000 (30 prescriptions reviewed in each facility, n = number of health care facilities for which data was available, year by year).
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devices in health-care facilities [20]. WHO, UNICEF and
UNFPA reaffirmed the need to supply auto-disable
syringes and safety boxes together for all consignments of
vaccines [5]. Similarly, WHO developed a strategy to
ensure that special attention is paid for the safe adminis-
tration of all types of injections in health care services.
WHO recommends that injection device security is
ensured in all health care facilities, including therapeutic
services, so that injectable medicines, diluents, single-use
injection devices and safety boxes are supplied in timely
manner in adequate quantities [6]. To practically assist
procurement officers and pharmacists in procuring injec-
tion devices of good quality, WHO developed a procure-
ment guide, [21] a quality assurance guide for injection
devices [22] and a procedure for assessing, in principle,
injection devices for the procurement by United Nations
agencies [23]. Following this new policy through use of
these tools should ensure injection device security. Injec-
tion device security, along with behaviour change and
sharps waste management should prevent injection-asso-
ciated infections in the future. Efforts to reduce overuse of
injections should continue and be monitored using stand-
ardized indicators [24].
Conclusion
In Burkina Faso, establishing pharmaceutical depots next
to health care facilities through the national policy of
essential medicines increased access to safe injection
devices and contributed substantially to safer injection
practices along with other factors, including an increased
consumer demand for safe injection devices. The better
access to single use injection devices was not parallelled
by an increase in injection prescriptions. However, health
care waste management policies need to address the
increased amount of sharps waste generated.
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